Acquisition Overview#
Gilead Sciences Inc. has successfully completed its acquisition of Arcellx Inc. for approximately $7.8 billion. The deal involves a cash payment of $115 per share, along with a contingent value right (CVR) of $5 per share. A CVR is a financial instrument that provides additional compensation based on future performance—in this case, contingent on sales of a specific therapy reaching $6 billion by 2029.
Details of the Transaction#
The acquisition grants Gilead full ownership of an investigational therapy called anitocabtagene autoleucel (anito-cel), which is designed to treat multiple myeloma, a type of blood cancer. This therapy was initially developed through a partnership between Arcellx and Kite, a subsidiary of Gilead. Following the acquisition, Arcellx’s stock will be delisted from the Nasdaq, as it becomes a wholly owned subsidiary of Gilead.
Financial Impact#
Gilead anticipates that this acquisition will impact its earnings per share (EPS) for 2026, reducing both its Generally Accepted Accounting Principles (GAAP) and non-GAAP EPS by approximately $5.57 to $5.67. However, the company expects only a modest dilution in earnings for 2026 and 2027, with potential growth in 2028, depending on regulatory approval for anito-cel.
Market Reactions#
Following the announcement, several analyst firms have adjusted their ratings for Arcellx. TD Cowen downgraded the stock to Hold, describing the acquisition offer as fair. Guggenheim and UBS also downgraded Arcellx to Neutral, with UBS raising its price target from $100 to $115. This reflects a cautious outlook on the stock following the acquisition, as analysts reassess the company’s future prospects.